PO.ET01.01 · 实验与分子治疗
Engineering the Next Wave of Antibody-Based Cancer Therapeutics
-
-
-
-
-
- 1761 1761 组织因子表达与卵巢透明细胞癌中B7-H4介导的免疫逃逸相关,并与临床前模型中对tisotumab vedotin的应答相关 Tissue Factor expression is associated with B7-H4-mediated immune evasion in ovarian clear cell carcinoma and with response to tisotumab vedotin in preclinical models Yutaro Mori, Ryo Tamura, Kotaro Takahashi, Kosuke Yoshihara
-
- 1763 1763 BSI-737——一种同类最佳的B7H3xPD-L1双特异性ADC,通过选择性杀伤和增强抗肿瘤免疫应答实现双重功能以清除肿瘤 BSI-737, a best-in-class B7H3xPD-L1 bi-specific ADC with dual function to eliminate tumor via selective killing and exacerbated anti-tumor immune response Hui-Han Hu, Xiaoyao Hao, Yue Gao, Hongyan Li, Jinyu Liu, Jinge Zhao, Yi Lu, Liezhou Ji, Zhigang Ma, Mingjiu Chen, Kedan Lin
- 1764 1764 MC003:一种新型双表位、双载荷、固定组合的化学免疫治疗抗体-药物偶联物,用于治疗表达叶酸受体α的卵巢癌 MC003: A novel bi-epitope, dual-payload, fixed-combination chemoimmunotherapy antibody drug conjugate for the treatment of folate receptor alpha-expressing ovarian cancer Seah H. Lim, Hailiang Zheng, Peipei Zhong
-
-
-
- 1768 1768 高灵敏度靶向质谱实现HLA提呈抗原的定量，用于TCR-T治疗靶点的发现 High-sensitivity targeted mass spectrometry enables quantification of HLA-presented antigens for TCR-T therapeutic target discovery Simonas Savickas, Anamarija Pfeiffer, Arthur Viodé, Liliana Malinovska, Oliver Bernhardt, Veronique Laforte, Lucy Yang, Roland Bruderer, Daniel Redfern, Yuehan Feng, Wayne Paes
- 1769 1769 LY4170156，一种靶向叶酸受体α的抗体偶联药物，在临床前卵巢癌模型中与标准治疗联用时表现出增强的抗肿瘤活性 LY4170156, an antibody-drug conjugate targeting folate receptor alpha, exhibits enhanced antitumor activity in combination with standard-of-care therapies in preclinical ovarian cancer models Zhaohai Lu, Chun Ping Yu, Jack A. Dempsey, Wei Guo Xu, Lisa Kays, Bonita D. Jones, Andrew Capen, Xueqian Gong
-
- 1771 1771 Trop2导向的抗体偶联药物（IMMU-132）与Apo2L/TRAIL联合治疗对三阴性乳腺癌（TNBC）的协同致死作用 Synergistic lethality of combination treatment with Trop2-directed antibody-drug conjugate (IMMU-132) and Apo2L/TRAIL in triple negative breast cancer (TNBC) Yonit Addissie, Yoshimi Endo Greer, Stan Lipkowitz
- 1772 1772 HER3靶向纳米生物颗粒递送5′-三磷酸修饰的FOXC1 siRNA，在HER3⁺癌症中诱导肿瘤消退和免疫激活 HER3-targeted nano-bioparticles deliver 5′-triphosphate-modified FOXC1 siRNA to induce tumor regression and immune activation in HER3⁺ cancers Amirhesam Babajani, Felix Alonso-Valenteen, James Teh, Nelyda Gonzalez, Simoun Mikhael, Michelle Wong, Xiaojiang Cui, Ravinder Abrol, Lali K. Medina-Kauwe
- 1773 1773 针对人胰腺细胞上过表达的整合素alpha6beta4的新型单克隆抗体的开发与表征 Development and characterisation of a novel monoclonal antibody against overexpressed integrin alpha6beta4 on human pancreatic cells Gustavo Arias, Angus G. Dalgleish, Izhar Bagwan, Said Khelwatty, Satvinder Mudan, Tony Walker, Helmout Modjtahedi
-
- 1775 1775 ACR335：一种新型cMET/EGFR双特异性双载荷抗体偶联药物，在实体瘤临床前模型中展现出强效而广谱的抗肿瘤活性 ACR335, a novel cMET/EGFR bispecific dual-payload antibody-drug conjugate, demonstrates potent and broad antitumor activity in preclinical models of solid tumors Zhenwei Miao, Feng Wang, Shanwei Weng, Li Yang, Wu Yao
- 1776 1776 ALK101sc：一种新型去岩藻糖基化、采用共同轻链、靶向EGFR和c-MET的双特异性抗体，展现出强效、广谱的抗肿瘤活性 ALK101sc, a novel afucosylated bispecific antibody targeting EGFR and c-MET with common light chain demonstrates potent, broad-spectrum antitumor activity Li Li, Hongwang He, Mengfan Peng, Meiyu Yang, Jiajia Pan, Hui Feng
- 1777 1777 FL116：一种PD-1/IL-18双特异性抗体，实现对PD-1⁺ T细胞的顺式激活并重塑抑制性肿瘤微环境（TME） FL116, a PD-1/IL-18 bispecific antibody, enables cis-activation of PD-1⁺ T cells and reshapes the suppressive tumor microenvironment (TME) Haiming Huang, Quanxiao Li, Xiaotuan Zhang, Liwen Ji, Yanling Wu, Dong Wei, Tianlei Ying
